Expressions of ERK and p-ERK in advanced prostate cancer.
- Author:
Jian HAN
1
;
Peng ZHANG
1
;
Lei ZHENG
1
;
Yong ZHANG
2
;
Ke-Nan WANG
1
;
Lian-Ming FAN
1
;
Hua-Dong XIE
1
;
Shu-Ren WANG
1
;
Zhi-Wei ZHANG
1
;
Qi-Fei WANG
1
;
Tao JIANG
1
Author Information
1. Department of Andrology, The First Hospital Affiliated to Dalian Medical University, Dalian, Liaoning 116011, China.
2. Texas Tech University Health Sciences Center School of Pharmacy Department of Biomedical Sciences,1300 S Coulter Street Amarillo,TX79106 USA.
- Publication Type:Journal Article
- Keywords:
ERK1/2;
p-ERK1/2;
phosphorylation;
prognosis;
advanced prostate cancer
- MeSH:
Biomarkers, Tumor;
metabolism;
Extracellular Signal-Regulated MAP Kinases;
metabolism;
Humans;
Male;
Mitogen-Activated Protein Kinase 1;
metabolism;
Mitogen-Activated Protein Kinase 3;
metabolism;
Neoplasm Grading;
Neoplasm Metastasis;
Prognosis;
Prostate;
enzymology;
Prostate-Specific Antigen;
metabolism;
Prostatic Hyperplasia;
enzymology;
pathology;
Prostatic Neoplasms;
enzymology;
mortality;
pathology
- From:
National Journal of Andrology
2017;23(5):406-411
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expressions of extracellular signal-regulated kinase (ERK) and p-ERK in benign and malignant prostate tissues, and whether it can be used as a marker for the prognosis of advanced prostate cancer (PCa).
METHODS:Using immunohistochemical Envision, we detected the expressions of ERK1/2 and p-ERK1/2 in 20 cases of benign prostatic hyperplasia (BPH) and 40 cases of advanced PCa and analyzed their correlation with PCa metastasis, Gleason score, PSA level, and prognosis.
RESULTS:The expression of ERK1/2 was remarkably higher in the advanced PCa than in the BPH cases (82.5% vs 55%, P<0.05), which was not associated with cancer metastasis, Gleason score, PSA level, or survival time of the patients with advanced PCa, and so was that of p-ERK1/2 (75.0% vs 35%, P<0.05), which was not associated with the Gleason score or PSA level of the PCa patients, either. The expression rates of p-ERK in the metastasis, non-metastasis, survival >5 yr, and survival ≤ 5 yr groups were 61.9%, 89.5%, 57.9%, and 90.5%, respectively, with statistically significant differences among these groups (P<0.05).
CONCLUSIONS:ERK1/2 and p-ERK1/2 proteins are highly expressed in advanced PCa and p-ERK1/2 is associated with the metastasis and prognosis of advanced PCa.
